Oxaliplatin induces a delayed immune-mediated hemolytic anemia: A case report and review of the literature

被引：17
作者：
Noronha, Vanita
Burtness, Barbara
Murren, John
Duffy, Thomas R.
机构：
[1] Mid Valley Oncol Hematol PC, Newburgh, NY 12550 USA
[2] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[3] Yale Univ, Sch Med, New Haven, CT USA
来源：
CLINICAL COLORECTAL CANCER | 2005年 / 5卷 / 04期
关键词：
bevacizumab; disease-free survival; FOLFOX regimens; monoclonal antibodies;
D O I：
10.3816/CCC.2005.n.041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We report a case of a 59-year-old woman with metastatic carcinoma of the ileocecal region who received FOLFOX (oxaliplatin/leucovorin/5-fluorouracil) and bevacizumab therapy and exhibited a partial remission with minimal side effects. She developed a mild self-limited episode of immune-mediated hemolytic anemia during her 16th cycle of chemotherapy, which precluded her from receiving further oxaliplatin. We review the literature on oxaliplatin-induced immune-mediated hemolysis, including its mechanism, presenting symptoms, laboratory features, management, and implications for future therapy.
引用
收藏
页码：283 / 286
页数：4
相关论文
共 22 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]   Oxaliplatin-related side effects: Characteristics and management [J].
Cassidy, J ;
Misset, JL .
SEMINARS IN ONCOLOGY, 2002, 29 (05) :11-20
[3]   An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma [J].
Chau, I ;
Webb, A ;
Cunningham, D ;
Hill, M ;
Rao, S ;
Ageli, S ;
Norman, A ;
Gill, K ;
Howard, A ;
Catovsky, D .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) :786-792
[4]   An immediate hemolytic reaction induced by repeated administration of oxaliplatin [J].
Chen, VMY ;
Thrift, KM ;
Morel-Kopp, MC ;
Jackson, D ;
Ward, CM ;
Flower, RL .
TRANSFUSION, 2004, 44 (06) :838-843
[5]   Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck [J].
Degardin, M ;
Cappelaere, P ;
Krakowski, I ;
Fargeot, P ;
Cupissol, D ;
Brienza, S .
ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1996, 32B (04) :278-279
[6]   Oxaliplatin-induced haemolytic anaemia [J].
Desrame, J ;
Broustet, H ;
de Tailly, PD ;
Girard, D ;
Saissy, JM .
LANCET, 1999, 354 (9185) :1179-1180
[7]   Oxaliplatin-induced Evan's syndrome [J].
Earle, CC ;
Chen, WY ;
Ryan, DP ;
Mayer, RJ .
BRITISH JOURNAL OF CANCER, 2001, 84 (03) :441-441
[8]   Immunohemolytic anemia following oxaliplatin administration [J].
Garufi, C ;
Vaglio, S ;
Brienza, S ;
Conti, L ;
D'Attino, RM ;
Girelli, G ;
Terzoli, E .
ANNALS OF ONCOLOGY, 2000, 11 (04) :497-497
[9]   CISPLATIN-INDUCED HEMOLYSIS [J].
GETAZ, EP ;
BECKLEY, S ;
FITZPATRICK, J ;
DOZIER, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 302 (06) :334-335
[10]   A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].
Goldberg, RM ;
Sargent, DJ ;
Morton, RF ;
Fuchs, CS ;
Ramanathan, RK ;
Williamson, SK ;
Findlay, BP ;
Pitot, HC ;
Alberts, SR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30
123